← Back to Analyst Consensus 
TERN Hold
Terns Pharmaceuticals, Inc.
Current Price —
Implied Upside —
Analysts 17
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Apr 27, 2026 | Oppenheimer | downgrade | Outperform → Perform | — | 52% |
| Apr 14, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 54% |
| Mar 31, 2026 | Truist Securities | downgrade | Buy → Hold | — | 54% |
| Mar 30, 2026 | Barclays | downgrade | Overweight → Equal-Weight | — | 53% |
| Mar 26, 2026 | Citizens | downgrade | Market Outperform → Market Perform | — | 47% |
| Mar 26, 2026 | TD Cowen | downgrade | Buy → Hold | — | 54% |
| Mar 25, 2026 | HC Wainwright & Co. | downgrade | Buy → Neutral | — | 44% |
| Dec 11, 2025 | Citizens | maintain | Market Outperform → Market Outperform | $57 | 47% |
| Dec 9, 2025 | Truist Securities | maintain | Buy → Buy | $56 | 54% |
| Dec 9, 2025 | Oppenheimer | maintain | Outperform → Outperform | $58 | 52% |
| Dec 9, 2025 | BMO Capital | maintain | Outperform → Outperform | $54 | 53% |
| Dec 9, 2025 | Barclays | maintain | Overweight → Overweight | $56 | 53% |
| Dec 9, 2025 | Mizuho | maintain | Outperform → Outperform | $54 | 52% |
| Dec 9, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $60 | 44% |
| Nov 26, 2025 | Citizens | maintain | Market Outperform → Market Outperform | $35 | 47% |
| Nov 25, 2025 | Barclays | maintain | Overweight → Overweight | $36 | 53% |
| Nov 19, 2025 | Truist Securities | maintain | Buy → Buy | $35 | 54% |
| Nov 18, 2025 | BMO Capital | maintain | Outperform → Outperform | $30 | 53% |
| Nov 13, 2025 | Mizuho | maintain | Outperform → Outperform | $33 | 52% |
| Nov 11, 2025 | Barclays | maintain | Overweight → Overweight | $28 | 53% |
| Nov 4, 2025 | Truist Securities | reiterate | Buy → Buy | $28 | 54% |
| Nov 4, 2025 | BMO Capital | maintain | Outperform → Outperform | $22 | 53% |
| Nov 4, 2025 | Barclays | maintain | Overweight → Overweight | $27 | 53% |
| Nov 4, 2025 | HC Wainwright & Co. | upgrade | Neutral → Buy | $20 | 44% |
| Nov 4, 2025 | Mizuho | maintain | Outperform → Outperform | $32 | 52% |
| Nov 3, 2025 | William Blair | upgrade | Market Perform → Outperform | $0 | 48% |
| Nov 3, 2025 | Jefferies | maintain | Buy → Buy | $35 | 52% |
| Oct 23, 2025 | JMP Securities | maintain | Market Outperform → Market Outperform | $15 | 53% |
| Oct 22, 2025 | Barclays | maintain | Overweight → Overweight | $14 | 53% |
| Oct 22, 2025 | Oppenheimer | maintain | Outperform → Outperform | $17 | 52% |
| Oct 22, 2025 | Mizuho | maintain | Outperform → Outperform | $9 | 52% |
| Oct 15, 2025 | Truist Securities | initiate | — → Buy | $20 | 54% |
| Sep 17, 2025 | Barclays | initiate | — → Overweight | $15 | 53% |
| May 13, 2025 | BMO Capital | maintain | Outperform → Outperform | $15 | 53% |
| Apr 21, 2025 | JMP Securities | reiterate | Market Outperform → Market Outperform | $20 | 53% |
| Feb 28, 2025 | William Blair | initiate | — → Market Perform | $0 | 48% |
| Dec 4, 2024 | JMP Securities | reiterate | Market Outperform → Market Outperform | $20 | 53% |
| Dec 4, 2024 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $7.5 | 44% |
| Dec 4, 2024 | Oppenheimer | maintain | Outperform → Outperform | $20 | 52% |
| Nov 13, 2024 | HC Wainwright & Co. | maintain | Neutral → Neutral | $7.5 | 44% |
| Oct 31, 2024 | Oppenheimer | initiate | — → Outperform | $17 | 52% |
| Sep 16, 2024 | BMO Capital | reiterate | Outperform → Outperform | $26 | 53% |
| Sep 10, 2024 | JMP Securities | maintain | Market Outperform → Market Outperform | $20 | 53% |
| Sep 3, 2024 | JMP Securities | reiterate | Market Outperform → Market Outperform | $15 | 53% |
| Aug 6, 2024 | BMO Capital | reiterate | Outperform → Outperform | $19 | 53% |
| May 14, 2024 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $5.5 | 44% |
| Apr 30, 2024 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $5.5 | 44% |
| Apr 30, 2024 | JMP Securities | reiterate | Market Outperform → Market Outperform | $15 | 53% |
| Mar 27, 2024 | UBS | maintain | Buy → Buy | $18 | 54% |
| Mar 18, 2024 | JMP Securities | maintain | Outperform → Outperform | $15 | 53% |
Price Target Trend
Apr 2, 2026 Latest: $53 Jul 18, 2026
EPS Estimates
+1q $-0.28
Lo: $-0.34 Hi: $-0.24
3 analysts ▲1
0y $-1.24
Lo: $-1.48 Hi: $-1.00
2 analysts ▲2
0q $-0.26
Lo: $-0.32 Hi: $-0.22
3 analysts ▲1
+1y $-1.56
Lo: $-1.82 Hi: $-1.29
3 analysts ▲2
Cross-Platform Signals
No cross-platform signals in the last 90 days